Amgen Inc. $AMGN Stock Position Reduced by Milestone Asset Management LLC

Milestone Asset Management LLC decreased its position in Amgen Inc. (NASDAQ:AMGN) by 82.9% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 3,059 shares of the medical research company’s stock after selling 14,819 shares during the quarter. Milestone Asset Management LLC’s holdings in Amgen were worth $1,290,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the company. State Street Corp boosted its stake in shares of Amgen by 38.2% during the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock worth $15,283,363,000 after purchasing an additional 11,656,755 shares during the last quarter. Bank of America Corp DE purchased a new stake in shares of Amgen during the second quarter worth about $1,831,903,000. Wellington Management Group LLP raised its position in shares of Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock valued at $993,031,000 after buying an additional 2,514,254 shares during the last quarter. BlackRock Inc. raised its position in shares of Amgen by 4.8% in the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock valued at $17,874,974,000 after buying an additional 2,261,544 shares during the last quarter. Finally, Assenagon Asset Management S.A. raised its position in shares of Amgen by 702.8% in the third quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock valued at $647,126,000 after buying an additional 1,344,010 shares during the last quarter. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Amgen News Summary

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported positive Phase 3 results for Tezspire in eosinophilic esophagitis. Nearly 70% of patients receiving the higher dose achieved remission after 24 weeks, potentially expanding the drug’s addressable market in a condition with limited treatment options. What Could Amgen 70% Remission Trial Result Mean For Its Pipeline?
• Positive Sentiment: UBS raised its price target for AMGN to $470, signaling greater confidence in the company’s outlook and supporting investor sentiment. UBS raises target for Amgen stock to USD 470.00
• Positive Sentiment: Investors are focusing on Amgen’s broader pipeline, including the MariTide obesity program, planned Phase 3 diabetes studies and recent regulatory momentum. These programs offer potential long-term growth beyond Amgen’s established products. Amgen Gains as Investors Appear to Lean on Pipeline and Regulatory Momentum
• Positive Sentiment: Erste Group Bank increased its FY2027 EPS forecast to $24.66 from $24.36, adding to evidence that some analysts see improving earnings potential.
• Positive Sentiment: A broader rotation away from technology stocks toward defensive and consumer-oriented companies may be helping support sentiment toward large pharmaceutical stocks.
• Neutral Sentiment: Amgen’s dividend yield is approximately 2.3%. Its dividend-growth prospects are being compared favorably with Merck’s because of Amgen’s reported cash-flow cushion, although the analysis does not represent a new dividend announcement. AMGN vs. MRK: Which Pharma Giant’s Dividend Actually Has Room to Grow
• Negative Sentiment: Risks remain: Bank of America Securities maintained a Sell rating, while recent insider activity showed seven sales and no purchases over six months. Some previously published analyst targets also remain well below the current trading range, highlighting valuation concerns. Bank of America Securities Remains a Sell on Amgen

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on AMGN shares. TD Cowen upped their price objective on shares of Amgen from $420.00 to $452.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. Mizuho boosted their price target on Amgen from $303.00 to $352.00 and gave the company a “neutral” rating in a report on Tuesday, August 18th. Robert W. Baird boosted their price target on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a report on Wednesday, August 5th. UBS Group increased their price target on Amgen from $430.00 to $470.00 and gave the stock a “buy” rating in a research note on Friday, October 9th. Finally, Wells Fargo & Company decreased their price objective on Amgen from $435.00 to $430.00 and set an “equal weight” rating on the stock in a report on Monday. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, sixteen have assigned a Hold rating and three have issued a Sell rating to the stock. According to data from MarketBeat.com, Amgen has a consensus rating of “Hold” and a consensus price target of $387.93.

Amgen Trading Up 1.9%

Shares of AMGN stock opened at $434.03 on Friday. The firm’s 50-day simple moving average is $415.11 and its 200-day simple moving average is $374.35. The company has a debt-to-equity ratio of 4.44, a current ratio of 1.37 and a quick ratio of 1.13. Amgen Inc. has a 1-year low of $288.00 and a 1-year high of $447.03. The firm has a market cap of $234.65 billion, a P/E ratio of 26.98, a PEG ratio of 3.12 and a beta of 0.41.

Amgen (NASDAQ:AMGN) last released its earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same period in the previous year, the firm earned $6.02 earnings per share. Amgen’s revenue was up 9.5% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. As a group, equities analysts forecast that Amgen Inc. will post 22.94 EPS for the current year.

Amgen Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, September 11th. Shareholders of record on Friday, August 21st were paid a dividend of $2.52 per share. The ex-dividend date of this dividend was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s dividend payout ratio (DPR) is currently 62.65%.

Insiders Place Their Bets

In related news, SVP Nancy Grygiel sold 2,970 shares of Amgen stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the transaction, the senior vice president owned 7,340 shares in the company, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, SVP Rachna Khosla sold 2,000 shares of the business’s stock in a transaction dated Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total value of $825,140.00. Following the sale, the senior vice president owned 6,404 shares of the company’s stock, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 6,222 shares of company stock worth $2,540,926. 0.85% of the stock is owned by company insiders.

Amgen Company Profile

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research and commercial activities focus on areas including oncology, cardiovascular disease, inflammation, bone health, neuroscience and rare diseases. The company uses biologic research, human genetics and other advanced technologies to develop targeted therapies and supports patients through treatment and disease-management services.

Amgen’s portfolio includes medicines such as Enbrel for inflammatory diseases; Prolia and Evenity for osteoporosis; Xgeva for cancer-related bone complications; Repatha for certain cardiovascular conditions; Otezla for inflammatory diseases; Aimovig for migraine prevention; Tezspire for severe asthma; and Lumakras for certain cancers.